Q-omics provides the consensus-scored RHPN1 profile across patient tissues and cancer cell-line models. RHPN1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHPN1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RHPN1 RNA expression shows 17,010 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where RHPN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHPN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHPN1 survival associations across molecular data types. RHPN1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHPN1 RNA expression–survival associations across cancer types. High RHPN1 expression shows unfavorable associations in KIRC, UCS, UVM, LIHC and LUSC, but favorable associations in STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHPN1 RNA expression.
This table summarizes RHPN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHPN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHPN1 shows higher tumor expression in COAD, KIRP, BLCA, LIHC, LUAD and STAD. The COAD box plot shows higher RHPN1 RNA expression in tumor versus normal tissue (log2 FC = +3.458, t-test p < 0.001).
This table shows molecular features associated with RHPN1 in patient tissues and cancer cell lines. In patient samples, RHPN1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHPN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
